NCT05037097View on ClinicalTrials.gov

A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 30, 2021

Primary Completion Date

December 19, 2023

Study Completion Date

December 19, 2023

Conditions
COVID-19SARS-CoV-2 InfectionCorona Virus Infection
Interventions
BIOLOGICAL

ARCT-165

Dose 3

BIOLOGICAL

ARCT-154

Dose 2

BIOLOGICAL

ARCT-021

Dose 1

Trial Locations (4)

1862

Arcturus Investigational Site 301, Diepkloof

64114

Arcturus Investigational Site 201, Kansas City

67207

Arcturus Investigational Site 202, Wichita

169608

Arcturus Investigational Site 101, Singapore

Sponsors
All Listed Sponsors
lead

Arcturus Therapeutics, Inc.

INDUSTRY